# Respicardia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/respicardia

- Industry: Medical Devices & Equipment
- Headquarters: Minnetonka, US
- Website: www.respicardia.com
- Total disclosed funding: $83M
- Latest round: Series D (Oct 28, 2014)
- Investors on record: 8

## About

Respicardia, Inc. focuses on innovative medical technology, specifically developing the rem ede® System, which treats central sleep apnea through an implantable phrenic nerve stimulator, enhancing patient breathing during sleep without masks or medications.Founded in 2006 in Minnetonka, US, Respicardia, Inc. is dedicated to addressing central sleep apnea (CSA). In April 2021, ZOLL Medical Corporation acquired Respicardia, Inc., with financial terms undisclosed. The company has engaged in a total of 8 deals since inception. Danny Sachs was a key figure in the founding of the company, while Bonnie Labosky currently serves as the CEO.Respicardia, Inc. develops the rem ede® System, an implantable phrenic nerve stimulator designed to treat moderate to severe central sleep apnea in adults. This system uniquely functions without traditional masks or medications, automatically restoring normal breathing patterns during sleep. It is primarily available in the United States and select international markets, including parts of Europe that recognize the CE Mark certification. The device is utilized by healthcare providers and sleep specialists to offer innovative treatment solutions for patients suffering from CSA.Respicardia, Inc. generates revenue through the sales of the rem ede® System and related medical devices, primarily via direct-to-consumer and business-to-business transactions. The revenue model involves sales to hospitals, clinics, and sleep disorder centers, where healthcare providers prescribe and implant the device. Following successful implantation, healthcare providers also offer follow-up services, enhancing the value of the initial transaction. The rem ede® System is marketed under a pricing structure that includes individual device pricing and potential service agreements for ongoing patient management and monitoring.Following the acquisition by ZOLL Medical Corporation in April 2021, Respicardia, Inc. is poised for strategic growth. The company plans to leverage new resources to enhance product design and expand its market presence. Specific plans include the development of new products aimed at improving the treatment of CSA and targeting expansion into additional international markets. Recent funding from the acquisition will support these initiatives, furthering Respicardia’s commitment to providing innovative solutions for patients affected by sleep apnea.

## Funding rounds

- Series D, Oct 28, 2014, $25M — Versant Ventures, Three Arch Partners, Affinity Capital Management, Accuitive Medical Ventures, Sorin Group
- Series D, Aug 28, 2013, $10M — Versant Ventures, Three Arch Partners, Affinity Capital Management
- Series C, Aug 10, 2010, $27M — Versant Ventures, Polaris Partners, Affinity Capital Management, Accuitive Medical Ventures, Abbott Laboratories
- Series B, Oct 1, 2008, $21M — Versant Ventures, Polaris Partners, Three Arch Partners, Affinity Capital Management, Accuitive Medical Ventures, RK Ventures Group

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B, Series C, Series D
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B, Series C
- Three Arch Partners (https://capitalatlas.ai/funds/three-arch-partners) — Series B, Series D
- Affinity Capital Management (https://capitalatlas.ai/funds/affinity-capital-management) — Series B, Series C, Series D
- Accuitive Medical Ventures (https://capitalatlas.ai/funds/accuitive-medical-ventures) — Series B, Series C, Series D
- RK Ventures Group — Series B
- Abbott Laboratories — Series C
- Sorin Group — Series D